Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717436 | 0.79 | ERN1 (0.57) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL13075057 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL2001240 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL10996327 | 0.78 | ALDH1A1 (0.38) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL2354362 | 0.76 | BCHE (0.59) | KDM4EALDH1A1HSD17B10CHRM2ADRA2A | |
| SCHEMBL17423201 | 0.75 | KDM4E (0.57) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL29628893 | 0.75 | KDM4E (0.57) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL4894495 | 0.74 | KDM4E (0.56) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL4580940 | 0.73 | KDM4E (0.45) | KDM4EALDH1A1GLAHPGDMAOA | |
| SCHEMBL1502392 | 0.73 | ALDH1A1 (0.62) | KDM4EALDH1A1GLAHPGDMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123469-A1 | N- or C- terminally modified small peptides | ZEALAND PHARMA A/S (DK) | 2007-05-31 | — | — | US | claimed |
| WO-1997027179-A2 | ANTIRETROVIRAL BASES | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | claimed |
| EP-0178790-B1 | PROCESSES AND MATERIALS FOR CARRYING OUT SPECIFIC BINDING ASSAYS | UNILEVER PLC (GB) | 1991-09-18 | — | — | EP | claimed |
| EP-0178790-A1 | Processes and materials for carrying out specific binding assays | UNILEVER PLC (GB) | 1986-04-23 | — | — | EP | claimed |
| WO-1986001899-A1 | PROCESSES AND MATERIALS FOR CARRYING OUT SPECIFIC BINDING ASSAYS | UNILEVER PLC (GB) | 1986-03-27 | — | — | WO | claimed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-7749969-B2 | N- or C- terminally modified small peptides | ZEALAND PHARMA A/S (DK) | 2010-07-06 | — | — | US | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070123469-A1 | N- or C- terminally modified small peptides | ZEALAND PHARMA A/S (DK) | 2007-05-31 | — | — | US | disclosed |
| WO-2007007060-A2 | N- OR C- TERMINALLY MODIFIED SMALL PEPTIDES | ZEALAND PHARMA A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
| US-5763681-A | ALPHA-2-ADAMANTYLIDENE-ALPHA-METHOXY-META-METHOXYTOLUENE AND RELATED COMPOUNDS AS INTERMEDIATES | TROPIX, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997027179-A2 | ANTIRETROVIRAL BASES | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| US-5225584-A | Phosphonate esters and trialkylsilyl phosphonate esters | TROPIX, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0178790-B1 | PROCESSES AND MATERIALS FOR CARRYING OUT SPECIFIC BINDING ASSAYS | UNILEVER PLC (GB) | 1991-09-18 | — | — | EP | disclosed |
| EP-0178790-A1 | Processes and materials for carrying out specific binding assays | UNILEVER PLC (GB) | 1986-04-23 | — | — | EP | disclosed |
| WO-1986001899-A1 | PROCESSES AND MATERIALS FOR CARRYING OUT SPECIFIC BINDING ASSAYS | UNILEVER PLC (GB) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123469-A1 | N- or C- terminally modified small peptides | PTMS, CYP11A1, CYP3A4 | KDM4E 2661/4885ALDH1A1 1790/4885GLA 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.